60 completed, 13 terminated, 6 recruiting, 6 unknown. 33 Phase 3, 25 Phase 2, 15 Not applicable, 14 Phase 4, 7 Phase 1.
Follow Sham injection: new trials by email Literature Review of Sham injection trials Research Report on Sham injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Quadriceps Motor Unit Adaptation to Simulated Knee Injury Joint Effusion via 60 mL Sterile Saline, Intra-articular Lidocaine, Sham injection - Muscle Inhibition, Knee Injury Simulation | Early Phase 1 | Recruiting | University of Central Florida | 45 | 2026-08-01 | 2026-05-01 |
| Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection) ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose) - Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Not yet recruiting | Zhongmou Therapeutics | 21 | 2026-06-25 | 2026-04-13 |
| A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy TO-O-1007 (low-dose), TO-O-1007 (high-dose), Sham injection - Geographic Atrophy Due to Age-Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Theratocular Biotek Co. | 31 | 2026-06-02 | 2026-06-25 |
| Intrauterine Device Insertion Pain Management Benzocaine 20%, Lidocaine 2%, Sham injection - IUD Insertion Pain, IUD Insertion | Phase 4 | Terminated | University of Missouri-Columbia | 1 | 2025-06-23 | 2026-04-21 |
| Efficacy of NSAID Peritendinous Injection for Acute Tendinitis Peritendinous NSAID injection, Control group (placebo) - Tendinitis, Acute Tendonitis | Not applicable | Active not recruiting | Taipei Medical University WanFang Hospital | 40 | 2025-02-10 | 2025-02-19 |
| Bupivacaine and Epinephrine Injection Study Sensorcaine with Epinephrine, Sham injection - Sinus Disease, Anesthesia | Phase 2 / Phase 3 | Recruiting | Amin Javer | 80 | 2024-11-15 | 2025-05-15 |
| ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs VIA Disc NP, Sham Injection - Degenerative Disc Disease, Disc Degeneration | Phase 2 | Active not recruiting | VIVEX Biologics, Inc. | 121 | 2024-10-04 | 2026-10-05 |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) Tarcocimab, Sham injection - Diabetic Retinopathy | Phase 3 | Completed | Kodiak Sciences Inc | 255 | 2024-05-01 | 2026-05-13 |
| Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial Methotrexate Injection, Methotrexate Infusion, Sham Injection - Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment | Phase 2 | Unknown | Cincinnati Eye Institute, Southwest Ohio | 860 | 2024-03-01 | 2024-09-19 |
| Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients ZM-02-L, ZM-02-H, ZM-02-S - Retinitis Pigmentosa | Early Phase 1 | Recruiting | Zhongmou Therapeutics | 12 | 2024-02-25 | 2026-03-31 |
| Genicular Nerve Block in Chronic Knee Osteoarthritis Genicular nerve block with prilocaine, genicular nerve block with prilocaine and triamcinolone, Sham injection - Gonarthrosis; Primary, Genicular Nerve Block | Not applicable | Completed | Haydarpasa Numune Training and Research Hospital | 81 | 2023-04-01 | 2025-11-28 |
| Effect of Injectable Platelet-rich Fibrin on the En Masse Retraction of Maxillary Anterior Teeth injectable platelet rich fibrin(i-prf), Sham Injection - Platelet-rich Fibrin | Not applicable | Unknown | Cairo University | 26 | 2022-12-01 | 2022-11-08 |
| The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Yutiq 0.18 MG Drug Implant, Sham Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Texas Retina Associates | 10 | 2022-10-05 | 2026-10-05 |
| Safety and Tolerability of EO2002 EO2002, Sham injection - Cataract, Endothelial Cell Loss, Corneal | Phase 1 | Recruiting | Asociación para Evitar la Ceguera en México | 32 | 2022-08-30 | 2025-12-08 |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) KSI-301, Sham injection - Non-proliferative Diabetic Retinopathy | Phase 3 | Terminated | Kodiak Sciences Inc | 253 | 2021-09-07 | 2024-09-05 |
| Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] Gene Therapy Product-MCO-010, Sham Injection - Retinitis Pigmentosa, Retinitis | Phase 2 | Completed | Nanoscope Therapeutics Inc. | 27 | 2021-07-13 | 2024-03-22 |
| ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration ONL1204 Ophthalmic solution, sham injection - Geographic Atrophy | Phase 1 | Completed | ONL Therapeutics | 28 | 2021-07-08 | 2024-11-19 |
| Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy NR082 injection, Sham Injection - Leber's Hereditary Optic Neuropathy (LHON) | Phase 2 / Phase 3 | Recruiting | Wuhan Neurophth Biotechnology Limited Company | 102 | 2021-06-18 | 2022-11-14 |
| Fascia Iliaca Compartment Block for Pain Management in Hip Fracture Patients fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml), paracetamol 1 gram IV, Rescue analgesic tramadol 100 mg IV if needed - Hip Fractures | Phase 4 | Completed | General Hospital Sveti Duh | 80 | 2021-04-21 | 2022-08-03 |
| Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye Aflibercept Injection, Sham injection - Retinopathy, Diabetic | Phase 4 | Withdrawn | University of Rochester | 2021-02-01 | 2021-05-05 |
Showing 20 of 91. Sign in to see all of them.
Macular Edema (18) · Retinal Vein Occlusion (11) · Diabetic Retinopathy (10) · Vision Disorders (10) · Macular Degeneration (7) · Diabetes Mellitus (6) · Retinal Diseases (5) · Geographic Atrophy (4) · Osteoarthritis, Knee (4) · Eye Diseases (3) · Retinal Degeneration (3) · Retinitis Pigmentosa (3) · Uveitis, Intermediate (3) · Uveitis, Posterior (3) · Acute Pain (2)
Novartis Pharmaceuticals (6) · Allergan (5) · Alcon Research (4) · Genentech, Inc. (4) · ThromboGenics (4) · Chengdu Kanghong Biotech Co., Ltd. (3) · Taipei Medical University WanFang Hospital (3) · EyePoint Pharmaceuticals, Inc. (2) · Halozyme Therapeutics (2) · Jaeb Center for Health Research (2) · Kodiak Sciences Inc (2) · The Jerzy Kukuczka Academy of Physical Education in Katowice (2) · Zhongmou Therapeutics (2) · Amin Javer (1) · Asan Medical Center (1)
United States (37) · Germany (13) · United Kingdom (12) · Canada (11) · China (11) · France (9) · Spain (9) · Israel (8) · Australia (7) · Czechia (7) · Italy (7) · Taiwan (7) · Japan (6) · Poland (6) · Switzerland (6)
Jason Ehrlich, M.D., Ph.D. (2) · Pablo Velazquez-Martin, MD (2) · Roman Rubio, M.D. (2) · Adam Marberger, DDS (1) · Adam Rosenberg, MD (1) · Alessandra Marini, MD (1) · Alexander J. Brucker, M.D. (1) · Alexander Kharlamov, M.D., Ph.D. (1) · Amir Aviram, MD (1) · Ayumu Manabe (1) · Bin Li, MD (1)
PMID 22965590, PMID 23415775, PMID 23699977, PMID 23706949, PMID 24768239, PMID 25148789, PMID 26050541, PMID 26452713, PMID 26584450, PMID 26992841, PMID 27234930, PMID 29752001, PMID 30419298, PMID 31047350, PMID 31047503, PMID 31668888, PMID 36774994, PMID 37585454, PMID 39680390, PMID 19584650, PMID 20008710, PMID 20427088, PMID 20980427, PMID 21220619, PMID 21278146, PMID 21420555, PMID 21459214, PMID 21571677, PMID 22169699, PMID 22721455, PMID 22965588, PMID 22999634, PMID 23168578, PMID 23177167, PMID 23411886, PMID 23761087, PMID 25439614, PMID 26678525, PMID 26802783, PMID 26908704, PMID 27402605, PMID 28185625, PMID 28498374, PMID 29080915, PMID 29127949, PMID 29140929, PMID 30140124, PMID 30350717, PMID 31262265, PMID 31902472
2018 (2), 2005 (1), 2015 (1), 2017 (1), R21AA027332 (1), U10EY014229 (1), U10EY014231 (1), U10EY018817 (1)